Roth Capital Downgrades Cypress Bioscience (CYPB) to Neutral
CYPB Hot Sheet
Rating Summary:0 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Roth Capital downgraded Cypress Bioscience (NASDAQ: CYPB) from Buy to Neutral. PT $6.50.
For more ratings news on Cypress Bioscience click here and for the rating history of Cypress Bioscience click here.
Shares of Cypress Bioscience closed at $6.45 yesterday, with a 52 week range of $2.06-$6.84.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For more ratings news on Cypress Bioscience click here and for the rating history of Cypress Bioscience click here.
Shares of Cypress Bioscience closed at $6.45 yesterday, with a 52 week range of $2.06-$6.84.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
